Determining the relative efficacy of highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 187, Issue 6, 2003, Pages 896-900

  Louie, Michael ^a   Hogan, Christine ^a   Di Mascio, Michele ^b   Hurley, Arlene ^a   Simon, Viviana ^a   Rooney, James ^c   Ruiz, Nancy ^d   Brun, Scott ^e   Sun, Eugene ^e   Perelson, Alan S ^b   Ho, David D ^a   Markowitz, Martin ^a,f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c GILEAD SCIENCES   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e ABBOTT LABORATORIES   (United States)

^f AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RNA DEGRADATION; VIROLOGY;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; ORGANOPHOSPHORUS COMPOUNDS; OXAZINES; PHOSPHONIC ACIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0037444053     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368164     Document Type: Article

References (16)

1. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12:2161-7.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Louie M, Markowitz M. Goals and milestones during treatment of HIV-1 infection with anti-retroviral therapy: a pathogenesis-based perspective. Antiviral Res 2002; 55:15-25.
4. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
5. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
6. Perelson A, Nelson P. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev 1999; 41:3-44.
7. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002; 2:28-36.
8. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
9. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 1998; 12:1483-90.
10. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45:1438-43.
11. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-5.
12. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. JAMA 2000; 283:381-90.
13. Fischl M, Ribaudo H, Collier A, et al. A randomized trial comparing 2 4-drug antiretroviral regimens with a 3-drug regimen in advanced HIV disease [abstract 41]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandra, VA: Foundation for Retrovirology and Human Health, 2002:67.
14. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl 1):S5-37.
15. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-43.
16. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96:15109-14.